BlackRock, Inc. 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-06-09 3:20 pm Sale |
2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BLACKROCK INC BLK |
117,707 4.800% |
-2,233 (-1.86%) |
Filing |
| 2022-06-09 3:20 pm Purchase |
2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BLACKROCK INC BLK |
117,707 4.800% |
117,707 (New Position) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BLACKROCK INC BLK |
119,939 6.100% |
-9,660 (-7.45%) |
Filing |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BLACKROCK INC BLK |
129,599 6.800% |
53,107 (+69.43%) |
Filing |
| 2020-05-08 10:58 am Sale |
2020-04-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BLACKROCK INC BLK |
76,492 4.300% |
-396 (-0.52%) |
Filing |